Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Transcatheter correction of SVASD a viable alternative to surgery

26 Mar 2020

Transcatheter correction of the superior sinus venosus atrial septal defect (SVASD) appears to be a viable substitute to surgical treatment in several patients, suggests a recent study.

Forty-eight consecutive adult SVASD patients undergoing assessment for correction were included in this review. Preprocedural evaluation included cross-sectional imaging and ex vivo simulation using printed or virtual 3-dimensional models.

Of the patients, 25 had transcatheter correction, with a further six awaiting stent implantation, and eight deemed to be technically unsuitable.

The procedure consisted of balloon test inflation in the anticipated stent landing zone with simultaneous trans-oesophageal echocardiography and pulmonary venography to confirm defect closure and unobstructed pulmonary venous drainage. This was followed by the placement of a 10-zig covered Cheatham platinum stent.

Stents between 5 and 8 cm long were implanted. Nine patients were implanted with a second, uncovered stent for anchoring. A high-pressure balloon protected the right upper pulmonary vein (RUPV) during stent implantation to prevent pulmonary venous obstruction in four patients.

No deaths were recorded over a median follow-up period of 1.4 years (interquartile range, 0.8–1.7 years). One patient had stent embolization, while another needed draining of the haemopericardium.

Unobstructed pulmonary venous return was confirmed after 3 months via cardiac computed tomography. In addition, one patient presented with a residual shunt at the latest follow-up.

“The SVASD is characterized by deficiency of the common wall between the superior vena cava and the RUPV, which is no longer committed to the left atrium,” the authors explained.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.